



## **InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference**

September 9, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 9, 2022-- **InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV)**, a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference, which runs from September 12 – 14, 2022. Dr. Toselli and company management will also be available to participate in virtual one-on-one meetings with registered investors attending the conference.

A webcast of Dr. Toselli's presentation will be available on the Investor Relations - Events section of the company website at <https://investors.invivotherapeutics.com/events>, beginning September 12, 2022 at 7:00 am ET.

### **About InVivo Therapeutics**

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit [www.invivotherapeutics.com](http://www.invivotherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220909005020/en/): <https://www.businesswire.com/news/home/20220909005020/en/>

### **Investor Contact:**

Bret Shapiro, Managing Partner  
CORE IR  
[brets@coreir.com](mailto:brets@coreir.com)  
(516) 222-2560

### **Media Contact**

Tom Donovan  
Ten Bridge Communications  
[tom@tenbridgecommunications.com](mailto:tom@tenbridgecommunications.com)  
(857) 559-3397

Source: InVivo Therapeutics Holdings Corp.